Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
KALA Kala Pharmaceuticals, Inc. daily Stock Chart
KALA [NASD]
Kala Pharmaceuticals, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-2.55 Insider Own1.10% Shs Outstand40.76M Perf Week-3.79%
Market Cap584.50M Forward P/E- EPS next Y-1.36 Insider Trans- Shs Float33.19M Perf Month-25.29%
Income-90.90M PEG- EPS next Q-0.42 Inst Own85.90% Short Float15.65% Perf Quarter14.16%
Sales5.80M P/S100.78 EPS this Y-10.60% Inst Trans0.81% Short Ratio4.84 Perf Half Y115.25%
Book/sh3.47 P/B2.93 EPS next Y24.90% ROA-48.30% Target Price- Perf Year65.74%
Cash/sh3.42 P/C2.97 EPS next 5Y- ROE-132.10% 52W Range3.24 - 14.68 Perf YTD175.34%
Dividend- P/FCF- EPS past 5Y-27.10% ROI-87.40% 52W High-30.79% Beta-
Dividend %- Quick Ratio11.90 Sales past 5Y67.90% Gross Margin63.20% 52W Low213.58% ATR0.78
Employees136 Current Ratio12.20 Sales Q/Q-21.40% Oper. Margin- RSI (14)35.34 Volatility6.29% 7.47%
OptionableYes Debt/Eq0.00 EPS Q/Q28.10% Profit Margin- Rel Volume0.89 Prev Close10.16
ShortableYes LT Debt/Eq0.50 EarningsMay 07 BMO Payout- Avg Volume1.07M Price10.16
Recom1.30 SMA20-11.78% SMA50-15.20% SMA20040.28% Volume0 Change0.00%
Jun-01-20Resumed Oppenheimer Outperform $21
May-27-20Reiterated H.C. Wainwright Buy $14 → $17
Mar-09-20Upgrade BofA/Merrill Neutral → Buy
Dec-17-19Downgrade BofA/Merrill Buy → Neutral $9 → $6
Mar-14-19Initiated Jefferies Buy $15
Jun-23-20 11:01AM  
Hedge Funds Have Never Been This Bullish On Kala Pharmaceuticals, Inc. (KALA)
Insider Monkey -5.35%
Jun-10-20 08:00AM  
Kala Pharmaceuticals Announces Virtual-Only Format for 2020 Annual Meeting of Stockholders
Business Wire
Jun-05-20 11:30AM  
Is Kala Pharmaceuticals (KALA) Stock Outpacing Its Medical Peers This Year?
Zacks
Jun-02-20 08:41AM  
JPMorgan: 2 Stocks to Buy for At Least 40% Upside Potential (And 1 to Avoid)
TipRanks
May-28-20 08:16AM  
Need To Know: Analysts Are Much More Bullish On Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Revenues
Simply Wall St.
May-27-20 08:00AM  
Kala Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference
Business Wire
May-26-20 11:41AM  
Top Ranked Momentum Stocks to Buy for May 26th
Zacks
08:00AM  
Kala Pharmaceuticals Announces FDA Acceptance of New Drug Application for EYSUVIS for Dry Eye Disease
Business Wire
May-19-20 11:30AM  
Has Kala Pharmaceuticals (KALA) Outpaced Other Medical Stocks This Year?
Zacks
May-09-20 10:01PM  
Kala Pharmaceuticals, Inc. (KALA) Q1 2020 Earnings Call Transcript
Motley Fool
May-07-20 10:05AM  
Kala Pharmaceuticals (KALA) Reports Q1 Loss, Misses Revenue Estimates
Zacks
08:23AM  
Kala Pharmaceuticals: Q1 Earnings Insights
Benzinga
07:00AM  
Kala Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
Business Wire
May-06-20 08:00AM  
Kala Pharmaceuticals to Present at BofA Securities 2020 Health Care Conference
Business Wire +10.04%
May-05-20 12:00PM  
Kala Pharmaceuticals (KALA) Is Up 2.56% in One Week: What You Should Know
Zacks
09:03AM  
Kala Pharmaceuticals' Shares March Higher, Can It Continue?
Zacks
May-04-20 08:00AM  
Kala Pharmaceuticals Resubmits New Drug Application for EYSUVIS for Dry Eye Disease
Business Wire +10.07%
May-01-20 11:30AM  
Is Kala Pharmaceuticals (KALA) Stock Outpacing Its Medical Peers This Year?
Zacks
Apr-30-20 08:00AM  
Kala Pharmaceuticals to Report First Quarter 2020 Financial Results and Host Conference Call
Business Wire -6.65%
Apr-17-20 04:01PM  
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Business Wire +10.20%
Apr-16-20 12:00PM  
Here's Why Momentum Investors Will Love Kala Pharmaceuticals (KALA)
Zacks
Apr-08-20 11:01AM  
The Zacks Analyst Blog Highlights: DHT, Summit Therapeutics, Sharps Compliance, Frontline and Kala Pharmaceuticals
Zacks
10:42AM  
Zacks.com featured highlights include: Kala Pharmaceuticals, Unicharm and Capcom
Zacks
Apr-07-20 11:30AM  
Has Kala Pharmaceuticals (KALA) Outpaced Other Medical Stocks This Year?
Zacks
Apr-03-20 04:01PM  
Kala Pharmaceuticals Announces Exercise of Underwriters Option to Purchase Additional Shares
Business Wire
Mar-20-20 08:30PM  
13D Filings
Barrons.com
Mar-15-20 04:24PM  
Insiders Roundup: Masimo, Hertz
GuruFocus.com
Mar-11-20 11:06AM  
Biotech Stock Roundup: NVAX, CANF Up on Coronavirus Treatment Updates & More
Zacks
10:50AM  
Oppenheimer: These 3 Stocks Are Ripe for Double-Digit Gains
TipRanks
Mar-10-20 11:02PM  
Kala Pharmaceuticals Announces Pricing of Public Offering of 16,000,000 Shares of Common Stock
Business Wire
04:44PM  
Kala Pharmaceuticals Announces Proposed Public Offering of Common Stock
Business Wire
11:30AM  
Is Kala Pharmaceuticals (KALA) Outperforming Other Medical Stocks This Year?
Zacks
09:31AM  
Kala Pharmaceuticals, Inc. (KALA) Shares March Higher, Can It Continue?
Zacks
09:24AM  
Top Ranked Momentum Stocks to Buy for March 10th
Zacks
Mar-09-20 06:00AM  
Kala Pharmaceuticals Announces Statistically Significant Results for Primary and Key Secondary Endpoints in STRIDE 3 Clinical Trial Evaluating EYSUVIS for Signs and Symptoms of Dry Eye Disease
Business Wire +26.27%
Mar-06-20 10:11AM  
Implied Volatility Surging for Kala Pharmaceuticals (KALA) Stock Options
Zacks
Feb-20-20 04:01PM  
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Business Wire
Feb-12-20 11:30AM  
Has Kala Pharmaceuticals (KALA) Outpaced Other Medical Stocks This Year?
Zacks
08:35AM  
Kala Pharmaceuticals (KALA) Reports Q4 Loss, Lags Revenue Estimates
Zacks
07:00AM  
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
Business Wire
Feb-09-20 03:22PM  
The Week Ahead In Biotech: SMID-Cap Earnings In The Spotlight
Benzinga
Feb-06-20 11:53AM  
Biogen Soars on Patent Win for MS Drug Tecfidera Over Mylan
Zacks +9.74%
08:00AM  
Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call
Business Wire
Feb-03-20 11:11AM  
Aimmune's Palforzia Wins FDA Approval for Peanut Allergy
Zacks +8.89%
Jan-30-20 11:10AM  
Intercept (ICPT) Concludes Enrollment in Study on NASH Drug
Zacks
Jan-22-20 09:45AM  
Biotech Stock Roundup: Updates From HZNP & CLVS, BioNTech to Acquire Neon
Zacks +5.30%
09:33AM  
3 Healthcare Stocks With Important Catalysts in Q1
TipRanks
Jan-15-20 08:00AM  
Kala Pharmaceuticals Announces Completion of Enrollment of STRIDE 3 Trial for EYSUVIS (KPI-121 0.25%) for Dry Eye Disease
Business Wire
Jan-14-20 09:21AM  
Investors Who Bought Kala Pharmaceuticals (NASDAQ:KALA) Shares A Year Ago Are Now Down 13%
Simply Wall St.
Jan-08-20 08:00AM  
Kala Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference
Business Wire +9.28%
Dec-19-19 09:53PM  
Is Kala Pharmaceuticals, Inc. (KALA) A Good Stock To Buy?
Insider Monkey
04:05PM  
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Business Wire
Dec-12-19 04:11PM  
3 Biotech Stocks That Offer the Highest Upside on Wall Street
TipRanks +12.86%
Nov-19-19 04:05PM  
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Business Wire
Nov-07-19 08:25AM  
Kala Pharmaceuticals (KALA) Reports Q3 Loss, Misses Revenue Estimates
Zacks
07:00AM  
Kala Pharmaceuticals Reports Third Quarter 2019 Financial Results
Business Wire
Nov-04-19 04:30PM  
Kala Pharmaceuticals to Report Third Quarter 2019 Financial Results and Host Conference Call
Business Wire
Oct-21-19 04:05PM  
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Business Wire
Oct-11-19 08:34AM  
What Kind Of Shareholders Own Kala Pharmaceuticals, Inc. (NASDAQ:KALA)?
Simply Wall St.
Sep-25-19 08:40AM  
Implied Volatility Surging for Kala Pharmaceuticals (KALA) Stock Options
Zacks
Sep-19-19 04:05PM  
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Business Wire
Aug-29-19 08:00AM  
Kala Pharmaceuticals to Present at Two Upcoming Investor Conferences in September
Business Wire
Aug-27-19 08:56AM  
A Holistic Look At Kala Pharmaceuticals, Inc. (NASDAQ:KALA)
Simply Wall St. -6.54%
Aug-23-19 11:24AM  
Keep Your Eye on These 4 Healthcare Stocks
Motley Fool
Aug-20-19 04:05PM  
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Business Wire
Aug-19-19 07:08AM  
Should You Buy These 3 Beaten-Down Stocks Now?
TipRanks
Aug-08-19 04:01PM  
Kala Pharmaceuticals Receives FDA Complete Response Letter for KPI-121 0.25% NDA and Plans to Respond with Data From STRIDE 3 Trial
Business Wire -9.98%
Aug-06-19 03:40PM  
Kala Pharmaceuticals Reports Disappointing Q2 Sales
Motley Fool -13.27%
02:23PM  
Kala Pharmaceuticals, Inc. (KALA) Q2 2019 Earnings Call Transcript
Motley Fool
09:45AM  
Kala Pharmaceuticals (KALA) Reports Q2 Loss, Lags Revenue Estimates
Zacks
07:00AM  
Kala Pharmaceuticals Reports Second Quarter 2019 Financial Results
Business Wire
Jul-30-19 04:05PM  
Kala Pharmaceuticals to Report Second Quarter 2019 Financial Results and Host Conference Call
Business Wire
Jul-22-19 08:02AM  
How Does Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Affect Your Portfolio Volatility?
Simply Wall St.
Jun-20-19 04:05PM  
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Business Wire
Jun-13-19 03:11PM  
Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Is Expected To Breakeven
Simply Wall St.
May-30-19 08:00AM  
Kala Pharmaceuticals to Present at Jefferies 2019 Healthcare Conference
Business Wire
May-17-19 04:05PM  
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Business Wire
May-16-19 02:15PM  
Kala Pharmaceuticals, Inc. (KALA) Q1 2019 Earnings Call Transcript
Motley Fool
May-09-19 08:15AM  
Kala Pharmaceuticals (KALA) Reports Q1 Loss, Tops Revenue Estimates
Zacks
07:08AM  
Kala Pharma: 1Q Earnings Snapshot
Associated Press
07:00AM  
Kala Pharmaceuticals Reports First Quarter 2019 Financial Results
Business Wire
May-02-19 08:00AM  
Kala Pharmaceuticals to Report First Quarter 2019 Financial Results and Host Conference Call
Business Wire
Apr-29-19 08:59AM  
Is the Options Market Predicting a Spike in Kala Pharmaceuticals (KALA) Stock?
Zacks
Apr-25-19 11:35AM  
Investors Who Bought Kala Pharmaceuticals (NASDAQ:KALA) Shares A Year Ago Are Now Down 52%
Simply Wall St.
Apr-18-19 04:05PM  
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Business Wire
Apr-01-19 08:00AM  
Kala Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference
Business Wire
Mar-14-19 10:24AM  
Implied Volatility Surging for Kala Pharmaceuticals (KALA) Stock Options
Zacks
Mar-11-19 04:12PM  
Kala Pharma: 4Q Earnings Snapshot
Associated Press +6.03%
04:01PM  
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
Business Wire
Mar-06-19 08:00AM  
Kala Pharmaceuticals to Present at Upcoming Investor Conferences in March
Business Wire -7.92%
Mar-04-19 08:00AM  
Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call
Business Wire
Feb-22-19 04:05PM  
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Business Wire +5.16%
Jan-18-19 04:05PM  
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Business Wire
Jan-07-19 07:00AM  
Kala Pharmaceuticals Announces the Launch of INVELTYS and the Hiring of a Specialty Ophthalmology Sales Organization
Business Wire +6.17%
Jan-04-19 07:52AM  
Kala Pharmaceuticals, Inc.s (NASDAQ:KALA) Path To Profitability
Simply Wall St. +12.12%
Jan-02-19 08:00AM  
Kala Pharmaceuticals to Present at 37th Annual J.P. Morgan Healthcare Conference
Business Wire +6.13%
Dec-28-18 07:20AM  
Detailed Research: Economic Perspectives on American Airlines Group, Sandstorm Gold, Kala Pharmaceuticals, Adecoagro S.A, Novagold Resources, and Atossa Genetics What Drives Growth in Today's Competitive Landscape
GlobeNewswire
Dec-26-18 07:00AM  
Kala Pharmaceuticals Announces New Drug Application for KPI-121 0.25% for Dry Eye Disease Has Been Accepted for Review by the U.S. Food and Drug Administration
Business Wire
Dec-19-18 04:05PM  
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Business Wire
Nov-23-18 08:00AM  
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Business Wire
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Watertown, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Trachtenberg EricSee RemarksJun 19Option Exercise5.1928,901149,99628,901Jun 22 04:06 PM
Reumuth MaryChief Financial OfficerJun 09Option Exercise2.6443,477114,77148,293Jun 11 04:58 PM
Brazzell Romulus KChief Medical OfficerApr 09Option Exercise2.9967,771202,377176,496Apr 13 08:38 AM
Chen HongmingChief Scientific OfficerMar 30Option Exercise2.3031,00071,30086,849Apr 01 04:43 PM
Bazemore ToddChief Operating OfficerMar 16Buy5.7510,00057,50010,000Mar 17 05:46 PM
Grunberg GregoryDirectorMar 13Buy7.892,534,85419,999,9982,534,854Mar 16 07:59 AM
Shah Rajeev M.DirectorMar 13Buy7.896,337,13549,999,99510,874,613Mar 13 06:47 PM
RA CAPITAL MANAGEMENT, L.P.DirectorMar 13Buy7.896,337,13549,999,99510,874,613Mar 13 06:45 PM
Rosen Howard BDirectorAug 19Option Exercise0.604,8242,8724,824Jun 29 09:54 PM
open in yahoo | open in reuters | open in google